=== Page 128 ===
IBA Annual Report 2023 
125. 3. Business combinations and other changes 
in the composition of the group 
3.1. ACQUISITIONS OF COMPANIES 
In a transaction closed on March 3, 2023, the 
Group acquired 100% of the shares of 
Fluidomica LD.A. The consideration paid is 
EUR 0.2 million, the variable consideration is 
still to be estimated and will be payable in 2026 
for an amount of maximum EUR 0.4 million. During the year: IBA set up two new 
subsidiaries: IBA Dosimetry India Private 
Limited in July 2023 and IBA Proton Therapy 
Israel Ltd in September 2023. 3.2.